Trailing-twelve-month (TTM) revenue is $234.13 Million. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $207,834,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $10,876,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-17 |
| Q1 FY2026Period ended 2026-03-31 | $6,560,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $8,857,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $234,127,000 |
Current P/S: $3,505,713,897 market capitalization ÷ $234,127,000 TTM revenue = 14.97x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:40:24.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $8.86M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:43:06.902Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Methionine Adenosyl Transferase2 A Program Research And Development | $16M | $9M | N/A | N/A |
| Methionine Adenosyl Transferase2 A Program Supply | $2M | $2M | $2M | N/A |
| Polymerase Theta Program Research And Development Service |
$234.13M
$234.13 Million
N/A
+45.80%
5 Year compound annual growth rate
1 Year
N/A
3 Year
+73.07%
5 Year
+45.80%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $218.71M | +$211.71M | +3024.43% |
| 2024 | $7.00M | ($16.39M) | (70.07%) |
| 2023 | $23.39M | ($27.55M) | (54.08%) |
| 2022 | $50.93M | +$22.99M | +82.28% |
| 2021 | $27.94M | +$8.40M | +43.01% |
TTM Growth
N/A
3-Year CAGR
+73.07%
5-Year CAGR
+45.80%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:43:06.902Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $14M |
| N/A |
| N/A |
| Research and Development Services | N/A | N/A | N/A | $162M |
|---|
| The Option | $17M | $18M | N/A | N/A |
|---|
| Werner Helicase Program Research And Development Service | $28M | $21M | N/A | N/A |
|---|
